About Calidi Biotherapeutics
We are committed to being at the forefront of cutting-edge research and innovation in the realm of oncology and arming the immune system to kill cancer.
At Calidi Biotherapeutics, we're advancing a series of ready-to-use product candidates. These are grounded in our cutting-edge platform that harnesses allogeneic stem cell technologies combined with viruses engineered to attack cancer, namely the vaccinia virus and adenovirus.
Calidi throughout the years
2023
Lorem ipsum dolor sit amet consectetur. Lectus duis adipiscing rhoncus vitae. Augue enim ullamcorper iaculis tristique amet quam. Aliquam amet in sed ut. Bibendum egestas id morbi pretium mauris.
2022
Lorem ipsum dolor sit amet consectetur. Lectus duis adipiscing rhoncus vitae. Augue enim ullamcorper iaculis tristique amet quam. Aliquam amet in sed ut. Bibendum egestas id morbi pretium mauris.
2021
Lorem ipsum dolor sit amet consectetur. Lectus duis adipiscing rhoncus vitae. Augue enim ullamcorper iaculis tristique amet quam. Aliquam amet in sed ut. Bibendum egestas id morbi pretium mauris.
2020
Lorem ipsum dolor sit amet consectetur. Lectus duis adipiscing rhoncus vitae. Augue enim ullamcorper iaculis tristique amet quam. Aliquam amet in sed ut. Bibendum egestas id morbi pretium mauris.
2019
Lorem ipsum dolor sit amet consectetur. Lectus duis adipiscing rhoncus vitae. Augue enim ullamcorper iaculis tristique amet quam. Aliquam amet in sed ut. Bibendum egestas id morbi pretium mauris.
2018
Lorem ipsum dolor sit amet consectetur. Lectus duis adipiscing rhoncus vitae. Augue enim ullamcorper iaculis tristique amet quam. Aliquam amet in sed ut. Bibendum egestas id morbi pretium mauris.
2017
Lorem ipsum dolor sit amet consectetur. Lectus duis adipiscing rhoncus vitae. Augue enim ullamcorper iaculis tristique amet quam. Aliquam amet in sed ut. Bibendum egestas id morbi pretium mauris.
Calidi through the years
The company was founded in 2014, and is based in San Diego, California. Calidi's first patents were filed in 2015, and later awarded to Calidi for coverage in the United States and in key international territories. The patents encompass several patent families foundational to our SuperNova technology, used alone, and in combination with modern immunotherapies such as checkpoint inhibitors.
In 2016, Calidi acquired our wholly-owned subsidiary, based in Bernried, Germany, which is a pillar in the company's Research & Development and Process Development activities. In 2021 Calidi exclusively licensed the NeuroNova technology from Northwestern University and the City of Hope. This technology was developed over 15 years, and has shown strong indications of efficacy in published clinical trial results.
